No Results Found
Try adjusting your search to find what you’re looking for.
9/08/2021
Alamar Biosciences Completes $80M Series B Fundraising to Bring Unprecedented Performance to the Proteomics Market
Alamar Biosciences, Inc., a precision proteomics company that brings both ultra-high sensitivity and massively parallel scale to proteomic analysis, announced today that it has closed its $80 million Series B financing round, bringing its total funding to $110 million. “Alamar has made great strides in developing its novel technologies. This financing will position Alamar to complete the develo...
Read More
8/30/2021
Genome Medical Announces Acquisition of GeneMatters and Closing of $60 Million Series C Financing
Today, we are proud to announce that we have raised $60 million in a Series C financing — just more than a year after our Series B close. In addition, we have acquired GeneMatters, a leading telehealth genetic counseling and software solutions company, and we welcome their team to the Genome Medical family.
Read More
8/17/2021
Company Spotlight – Actym Therapeutics
“We’ve been impressed by Actym’s STACT platform because it’s both systemic and localized,” said Alexis Ji, Ph.D., Partner at Illumina Ventures. “In other words, it’s administered systemically, which is ideal to tackle metastases, but homes in on tumors and avoids healthy tissues, to minimize side effects. Potentially, this approach could increase both efficacy and safety.”
Read More
7/20/2021
Company Spotlight – Kallyope
“Kallyope is leveraging many of the same sophisticated technologies being used to map neural circuits in the brain to understand the cross-talk between the gut and the brain,” said Nick Naclerio, Ph.D., Founding Partner at Illumina Ventures. “The goal is to develop a comprehensive understanding of gut-brain circuits and target those for therapeutic advantage.”
Read More
